Boehringer Ingelheim reaffirms its leading position in hatchery vaccination with its vector vaccines at IPPE 2019

  • Vaxxitek® HVT + IBD continues to lead in hatchery vector vaccination worldwide
  • Newxxitek® HVT + ND is Boehringer Ingelheim’s latest vectored vaccine against Newcastle disease

Gainesville, GA, USA, 11 February 2019 – Boehringer Ingelheim will exhibit at the 2019 International Producing and Processing Expo (IPPE), the world’s largest poultry exhibition held in Atlanta, GA, USA, with its vector vaccines Vaxxitek® HVT + IBD and Newxxitek® HVT + ND.

Vaxxitek® HVT + IBD

Vaxxitek® HVT + IBD protects against two major immunosuppressive diseases: Infectious Bursal Disease (IBD) and Marek’s disease (MD). In October 2018, Boehringer Ingelheim celebrated a milestone of over 100 billion birds vaccinated with VAXXITEK® HVT + IBD worldwide since its launch in 2006.

To date, Vaxxitek® HVT + IBD is registered in more than 75 countries. It was launched in 2006 in Brazil and since then, in Europe, Middle East, Africa and China.

Newxxitek® HVT + ND

Newxxitek, the latest vectored Newcastle disease technology produced by Boehringer Ingelheim, protects flocks against Newcastle disease, even velogenic strains with no adverse reaction post-vaccination.

Jerome Baudon, Head of Poultry

Newxxitek® HVT + ND was launched in 2018 in velogenic Newcastle areas such as Peru, Egypt, Philippines and Thailand.

“Over the world, our hatchery vector vaccines help simplify the vaccination programme and contribute significantly to improve the live production performance of poultry producers,” said Jerome Baudon, Head of Poultry Strategic Business Unit at Boehringer Ingelheim.